National Consumers League Welcomes the Appeals Court Ruling Backing FDA’s Decision to Remove GLP-1 Drugs from the Shortage List
September 9, 2026: Washington, DC – As an organization focused on the safety of GLP-1 weight loss drugs, the National Consumers League welcomes the August 27 ruling by the US Court of Appeals for the Fifth Circuit affirming the Food and Drug Administration’s (FDA) decision to remove the popular GLP-1 weight loss drug semaglutide from its drug shortage list as lawful and correct.







